Explore

Rapid Read Rapid Read
GRAIL's Galleri Test Enhances Early Cancer Detection at ASCO Meeting

GRAIL's Galleri Test Enhances Early Cancer Detection at ASCO Meeting

GRAIL, Inc. has presented the results of its PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study involved 35,878 participants and evaluated the Galleri multi-cancer early detection (MCED) test. The test screens for over 50 types of cancer, including those without current screening options, such as pancreatic and ovarian cancers. The Galleri test demonstrated a 6.5-fold increase in cancer detection when added to standard screenings for breast, colorectal, cervical, and lung cancers. Notably, 71% of the new cancers detected were in stages I-III, allowing for potentially curative treatments. The test also showed a low false positive rate and high accuracy in predicting the cancer signal origin, facilitating efficient diagnostic evaluations.
Rapid Read Rapid Read
GRAIL's NHS-Galleri Trial Shows Significant Reduction in Stage IV Cancer Diagnoses

GRAIL's NHS-Galleri Trial Shows Significant Reduction in Stage IV Cancer Diagnoses

GRAIL, Inc. has announced the results of its NHS-Galleri trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial, conducted in collaboration with NHS England, evaluated the Galleri multi-cancer early detection (MCED) test. Over three years, the trial involved 142,250 participants aged 50 to 77. The results showed a 22% reduction in Stage IV cancer diagnoses in the second screening round and a 26% reduction in the third round. The Galleri test increased cancer detection rates four-fold when added to standard screening, and reduced emergency cancer diagnoses by 25%. The trial aims to detect cancers earlier, potentially allowing for curative treatment.
Rapid Read Rapid Read
Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection

Grail, a healthcare company based in Silicon Valley, has developed a $950 blood test called Galleri, designed to detect over 50 types of cancer early. The company presented its largest study at the American Society of Clinical Oncology meeting in Chicago, involving over 140,000 older participants in the UK. The study aimed to determine if the Galleri test could detect cancer before it reached advanced stages. While the test identified additional cancer cases, it missed a significant number, with a sensitivity of around 30%. The test is not yet FDA-approved but is available in the U.S. with a prescription. Despite its limitations, the test showed potential in detecting certain early-stage cancers, such as ovarian and esophageal cancers.
Rapid Read Rapid Read
Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail, a Silicon Valley healthcare company, has presented its largest study to date on the Galleri blood test at the American Society of Clinical Oncology meeting in Chicago. The test, priced at $950, aims to detect over 50 types of cancer by identifying cancer DNA in the bloodstream. The study involved more than 140,000 older individuals in the UK, assessing the test's ability to detect cancer before it reaches advanced stages. While the test increased cancer detection rates when combined with standard screenings, it was less effective at identifying early-stage cancers, which are generally easier to treat. The test is not yet FDA-approved but is available in the U.S. with a prescription.
Reuters Reuters
Experimental Novartis radiopharma drug shows promise in early study

Experimental Novartis radiopharma drug shows promise in early study

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.
Trendline Trendline
Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO
Rapid Read Rapid Read
Innovent's IBI363 Shows Promising Survival Benefits in Immunotherapy-Resistant Lung Cancer

Innovent's IBI363 Shows Promising Survival Benefits in Immunotherapy-Resistant Lung Cancer

Innovent Biologics has announced promising results from a Phase 1 proof-of-concept clinical study of its PD-1/IL-2α-bias bispecific fusion protein, IBI363, in treating advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). The study, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, involved 136 subjects with NSCLC who received IBI363 monotherapy. The results showed significant survival benefits, particularly in patients with squamous NSCLC and those with a smoking history. The median overall survival (OS) for patients in the 3 mg/kg dose group reached 18.2 months for squamous NSCLC and 15.2 months for adenoNSCLC. The study also highlighted a favorable safety profile for IBI363, with manageable adverse events.
Rapid Read Rapid Read
Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results for their next-generation selective RET inhibitor, lunbotinib fumarate, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study focused on patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The trial included 71 pre-treated patients and 92 treatment-naïve patients, showing an objective response rate of 81.3% in treatment-naïve and 87.1% in pre-treated patients. The drug demonstrated significant efficacy, particularly in patients with central nervous system metastases, achieving a 30% intracranial complete response rate. Lunbotinib fumarate was well tolerated, with minimal treatment-related adverse events leading to discontinuation.
Rapid Read Rapid Read
Phase III Study of Sacituzumab Tirumotecan Shows Promising Results for Lung Cancer Treatment

Phase III Study of Sacituzumab Tirumotecan Shows Promising Results for Lung Cancer Treatment

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of their Phase III OptiTROP-Lung05 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab as a first-line treatment for non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥1%. The study involved 413 patients and demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to pembrolizumab alone. The combination therapy showed a median PFS not reached versus 5.7 months for pembrolizumab alone, with a 12-month PFS rate of 62.4% versus 29.0%. The study also reported a positive trend in OS and manageable safety profiles.
Rapid Read Rapid Read
FDA Grants Breakthrough Device Designation to Gene Solutions' SPOT-MAS 10 for Cancer Screening

FDA Grants Breakthrough Device Designation to Gene Solutions' SPOT-MAS 10 for Cancer Screening

Gene Solutions, a biotechnology company, has received the U.S. FDA Breakthrough Device Designation for its SPOT-MAS 10 multi-omic blood test. This test is designed to detect cancer-associated signals by analyzing circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm. The test is intended for use as an adjunctive screening tool in asymptomatic adults aged 40 and older, covering various cancers such as breast, lung, and colorectal. The designation highlights the test's potential to provide more effective diagnosis of life-threatening diseases compared to current options. SPOT-MAS 10 aims to complement existing screening programs and expand opportunities for cancers lacking established pathways.
Trendline Trendline
Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer Treatment

Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer Treatment

Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer Treatment
Trendline Trendline
Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer

Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer

Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer